CENTERVILLE, MA--(Marketwire - March 16, 2011) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has commenced marketing a clean-air rental program specifically designed for the Hospitality Industry.
The program has been branded as UV Flu "Purity+" Clean Air System, and delivers an aggressively cost effective alternative for hotels and casinos to offer smoke, odor and contaminant-free rooms for their guests. UV Flu Representatives deodorize and monitor contaminants after placing a ViraTech UV-400 in the optimal location within those rooms operating in this innovative new program.
The UV-400 units are designed to kill any bacteria, allergens, and other contaminants, while also reducing any smoke and pet odors with increasing efficacy as room air is passed through the unit multiple times per hour. Company representatives are scheduled at pre-calculated intervals to monitor the room to ensure the UV-400 is performing optimally.
"The UV Flu 'Purity+' Clean Air System offers a significant opportunity for hotel management to increase their REVPAR (revenues per room), improve the level of guest satisfaction, and to decrease the number of room nights lost due to smoke odors in non-smoking rooms," said John Lennon, President of UV Flu. "Our research has shown that in some properties, as many as 1 out of 10 rooms identified as non-smoking exhibited residual smoke odors. The UV-400 can actually process smoke odors as they're being generated, while also killing all other organic contaminants."
Mr. Lennon continues, "Experienced hoteliers know that guests who enjoy fresh-smelling rooms feel healthier and sleep more soundly and report that a pleasurable experience is the key to return visits. Most seasoned travelers are perfectly willing to spend extra for this guaranteed level of service delivery."
"Our ability to provide hotel operators the option to buy, lease, and now rent our UV-400 along with a service program, gives property management the flexibility to find a solution that fits their specific needs. In our first week since we introduced the program we have been asked to provide proposals to properties with a combined room count approaching 20,000 rooms and we believe this momentum is sure to increase in the coming weeks," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOCs (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO